Full history for every metric is available with a Kvantra account
Alimera Sciences, Inc. (ALIM)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 47 | 54 | 51 | 59 | 54 | 81 | 100 |
| Operating profit | $m | -2 | 0 | |||||
| Net profit | $m | -16 | -10 | -5 | -4 | -18 | -20 | -15 |
| EPS reported | $ | -0.79 | -0.28 | |||||
| Operating cashflow per share | $ | -0.56 | -0.56 | |||||
| Capex per share | $ | 2.95 | 2.95 | |||||
| FCF per share | $ | -3.51 | -3.51 | |||||
| Free cash flow | $m | -90 | -6 | |||||
| Net debt | $m | 54 | 59 | |||||
| Book value equity | $m | 46 | 39 | |||||
| Book value per share | $ | 1.81 | 0.71 | |||||
| Number of shares | m | 25.56 | 54.38 | |||||
| DPS (TTM paid) | $ | 0.05 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.39 | 7.77 | |||||
| P/S LTM | x | 1.37 | 3.02 | |||||
| P/FCF LTM | x | -1.23 | -51.79 | |||||
| EV/EBITDA LTM | x | -148.64 | 31.69 | |||||
| EV/Sales LTM | x | 2.05 | 3.62 | |||||
| Earnings Yield LTM | % | -18.23% | -14.22% | |||||
| FCF Yield | % | -81.31% | -1.93% | |||||
| Quality | ||||||||
| ROE | % | -43.60% | -159.01% | |||||
| ROIC | % | -1.46% | -1.46% | |||||
| Operating margin | % | -2.39% | -2.39% | |||||
| Gross margin | % | 75.75% | 75.75% | |||||
| FCF/Sales | % | -111.19% | -111.19% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +49.19% | +69.78% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 1.14% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -6.25% | -9.13% | |||||
| FCF/Debt | x | -1.33 | -0.08 | |||||
| Net Debt/EBITDA | x | -49.60 | -49.60 | |||||
| EBIT/Net interest | x | -0.19 | -0.19 | |||||
| Net debt/market cap | % | 49.34% | 19.70% | |||||
| Net debt/Equity | x | 1.18 | 1.53 | |||||
| Gross debt/equity | x | 1.46 | 1.86 | |||||
Company overview
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Alimera Sciences, Inc. (ALIM)
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free